Diplomat Pharmacy, Inc. (NYSE: DPLO)
Hagens Berman Sobol Shapiro LLP alerts investors in Diplomat Pharmacy, Inc. (NYSE: DPLO) to the April 25, 2019 Lead Plaintiff deadline in the securities class action pending in the U.S. District Court for the Central District of California.
If you purchased or otherwise acquired shares of DPLO between February 26, 2018 and February 21, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information, contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing DPLO@hbsslaw.com.
According to the complaint, during the class period Defendants misled investors about Diplomat’s success in integrating and growing its pharmacy benefit management (“PBM”) business.
On February 22, 2019, Defendants’ announced they delayed releasing 2018 financial results, expected to record PBM-related impairment charges totaling approximately $630 million, and withdrew preliminary 2019 full-year outlook provided in January 2019.
This news drove the price of Diplomat shares down $7.59, or down about 56%, to close at $5.87 that day.
“We’re focused on investors’ losses and whether Defendants’ statements about Diplomat’s core PBM business may have misled investors,” said Hagens Berman partner Reed Kathrein.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.